Cover Image

SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities

This editorial comments on the report on a 2023 multistakeholder workshop addressing the development of sodium-glucose cotransporter-2 inhibitors for children with chronic kidney disease. Despite adult trials showing strong renal and cardiovascular benefits, pediatric studies are lacking because reg...

Full description

Saved in:
Bibliographic Details
Main Author: Schaefer, Franz (Author)
Format: Article (Journal)
Language:English
Published: January 2026
In: Kidney international
Year: 2026, Volume: 109, Issue: 1, Pages: 2-5
ISSN:1523-1755
DOI:10.1016/j.kint.2025.10.003
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1016/j.kint.2025.10.003
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0085253825008452
Get full text
Author Notes:Franz Schaefer

MARC

LEADER 00000naa a2200000 c 4500
001 1968005803
003 DE-627
005 20260407130606.0
007 cr uuu---uuuuu
008 260407s2026 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.kint.2025.10.003  |2 doi 
035 |a (DE-627)1968005803 
035 |a (DE-599)KXP1968005803 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schaefer, Franz  |d 1961-  |e VerfasserIn  |0 (DE-588)1023365383  |0 (DE-627)718365577  |0 (DE-576)366705598  |4 aut 
245 1 0 |a SGLT-2 inhibition in pediatric CKD  |b advances, challenges, and opportunities  |c Franz Schaefer 
264 1 |c January 2026 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 02. Januar 2026 
500 |a Gesehen am 07.04.2026 
520 |a This editorial comments on the report on a 2023 multistakeholder workshop addressing the development of sodium-glucose cotransporter-2 inhibitors for children with chronic kidney disease. Despite adult trials showing strong renal and cardiovascular benefits, pediatric studies are lacking because regulatory waivers excluded this population. Workshop participants emphasized urgent medical need, but also highlighted challenges: pediatric chronic kidney disease differs from adults, with congenital anomalies and nonglomerular disorders predominating, slower progression, and less proteinuria, limiting extrapolation from adult data. Safety concerns specific to children include dehydration, infections, and growth, bone, and neurodevelopmental effects. Lessons from adult trials underscore the need for pediatric-specific end points and biomarkers, including for cardiovascular outcomes. Recent regulatory actions, including the US Food and Drug Administration’s mandate for pediatric empagliflozin studies, mark progress. Upcoming clinical trials (A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease [EMPA-KIDNEY-Kids], Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients [DOUBLE-PROTECT] Alport) will require collaborative international efforts by the pediatric nephrology community to close the knowledge gap and ensure equitable access to renoprotective therapies for children with chronic kidney disease. 
650 4 |a disease progression 
650 4 |a pediatric CKD 
650 4 |a pharmacologic renoprotection 
650 4 |a SGLT2 inhibitors 
773 0 8 |i Enthalten in  |t Kidney international  |d New York, NY : Elsevier, 1972  |g 109(2026), 1 vom: Jan., Seite 2-5  |h Online-Ressource  |w (DE-627)32046637X  |w (DE-600)2007940-0  |w (DE-576)091143004  |x 1523-1755  |7 nnas  |a SGLT-2 inhibition in pediatric CKD advances, challenges, and opportunities 
773 1 8 |g volume:109  |g year:2026  |g number:1  |g month:01  |g pages:2-5  |g extent:4  |a SGLT-2 inhibition in pediatric CKD advances, challenges, and opportunities 
856 4 0 |u https://doi.org/10.1016/j.kint.2025.10.003  |x Resolving-System  |x Verlag  |z kostenfrei  |3 Volltext  |7 0 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0085253825008452  |x Verlag  |z kostenfrei  |3 Volltext  |7 0 
951 |a AR 
992 |a 20260407 
993 |a Article 
994 |a 2026 
998 |g 1023365383  |a Schaefer, Franz  |m 1023365383:Schaefer, Franz  |d 910000  |d 910500  |d 50000  |e 910000PS1023365383  |e 910500PS1023365383  |e 50000PS1023365383  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 1  |x j  |y j 
999 |a KXP-PPN1968005803  |e 4948658065 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Online verfügbar: 02. Januar 2026","Gesehen am 07.04.2026"],"relHost":[{"corporate":[{"role":"isb","display":"International Society of Nephrology"}],"recId":"32046637X","origin":[{"publisherPlace":"New York, NY ; Oxford [u.a.] ; [Erscheinungsort nicht ermittelbar] ; Basingstoke","dateIssuedKey":"1972","publisher":"Elsevier ; Blackwell ; Wiley-Blackwell ; Nature Publishing Group","dateIssuedDisp":"1972-"}],"disp":"SGLT-2 inhibition in pediatric CKD advances, challenges, and opportunitiesKidney international","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1523-1755"],"zdb":["2007940-0"],"eki":["32046637X"]},"note":["Gesehen am 20.08.20"],"title":[{"title":"Kidney international","title_sort":"Kidney international","subtitle":"official journal of the International Society of Nephrology"}],"pubHistory":["1.1972 -"],"language":["eng"],"part":{"pages":"2-5","issue":"1","year":"2026","extent":"4","volume":"109","text":"109(2026), 1 vom: Jan., Seite 2-5"},"type":{"bibl":"periodical","media":"Online-Ressource"}}],"name":{"displayForm":["Franz Schaefer"]},"title":[{"title_sort":"SGLT-2 inhibition in pediatric CKD","title":"SGLT-2 inhibition in pediatric CKD","subtitle":"advances, challenges, and opportunities"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1968005803","origin":[{"dateIssuedKey":"2026","dateIssuedDisp":"January 2026"}],"id":{"eki":["1968005803"],"doi":["10.1016/j.kint.2025.10.003"]},"physDesc":[{"extent":"4 S."}],"person":[{"display":"Schaefer, Franz","role":"aut","family":"Schaefer","given":"Franz"}]} 
SRT |a SCHAEFERFRSGLT2INHIB2026 

Similar Items